We are proud and pleased to have received the award for the Best Market Data Service at the Systems in the City Fintech Awards during an online ceremony hosted on 10th September 2020. In addition, Ricky Strachan, Sales Manager at Infront in the UK, received an award for Sales Manager of the Year.
Who is the new Infront and what does it stand for?
Read the following interview about our new market positioning, our product strategy and how you will benefit from it. Kristian Nesbak, CEO of Infront, Florent Grauer as CPO of Infront and Afsheen Azam as Head of Customer Support, Europe at Infront will give you some insights.
The SIPUGday focuses since the start on market data and related technologies, services and products in the front, back and middle office. Regulations and their impact on data are also a topic for our audience.
Infront and vwd will be represented on site by Ivo Bieri, Managing Director Switzerland. He will be happy to inform you about the advantages for you of the merger of the two companies in the future. We look forward to a lively exchange with you!
October 27, 2020
We cordially invite you to the webinar "Infront Portfolio Manager | Currency Switching and Extended Restriction Monitoring" on 05.11.2020 from 11.00 to 12.00 hrs.
The Portfolio Manager is the perfect portfolio management solution for Private Banking and Wealth Management. The software supports all process stages of portfolio management, extensive chart and securities analyses and flexible customer reporting. The event will be held in German language, please contact us, if you’re interested in an English version.
An introduction is followed by demonstrations of the new "currency conversion" functionality and the improved "restriction monitoring" functionality. Finally, we will be available for questions.
The FUCHS|RICHTER test authority is the first address in the German-speaking world for independent market tests in the areas of wealth and private banking. The "crowning glory" is the Private Banking Summit in November every year. There, the best asset managers in the German-speaking countries are awarded and honored.
Due to Corona, the summit concept has been consistently changed. This year, the Private Banking Summit will take place for the first time completely digitally on November 16 at 3 p.m. What else you can expect and how you can participate, you can find out in the following video.
Further information will be available shortly here or under Quantalys Inside 2020.
We will again be represented at the DKF this year and look forward to your visit to our stand.
Further information will be available here soon or on the official DKF 2021 website.
As in previous years, COPS invites to their annual COPS user meeting this year from 24 to 25 June 2021 at the Seehotel Rust in Rust on Neusiedlersee.
The customers can expect a versatile and varied program, ranging from innovations in software solutions, successful project reports to practical application examples.
As a strategic partner, COPS gives us the opportunity to present our company and our solutions and show-case the cooperation with COPS.
You can find further information here...
16.09.2020 BUSINESS WIRE: Takeda to Divest TachoSil® to Corza Health for €350 Million
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
OSAKA, Japan --(BUSINESS WIRE)-- 16.09.2020 --
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest its TachoSil® Fibrin Sealant Patch (“TachoSil®”) to Corza Health, Inc. (“Corza Health”). Corza Health was formed in 2019 as a partnership between private equity firm GTCR and healthcare industry veteran Gregory T. Lucier to build a market-leading healthcare business with a particular focus on the broader medical technology and life sciences sector. Takeda will receive €350 million in cash upon closing of the transaction, which is subject to customary legal and regulatory closing conditions.
TachoSil® is a surgical patch trusted by medical professionals globally to deliver safe, fast and reliable bleeding control. Takeda recorded full year net sales for TachoSil® of approximately $160 million USD in the fiscal year ended March 31, 2020.
Costa Saroukos, Chief Financial Officer, Takeda, said, “This announcement continues Takeda’s strong momentum toward optimizing our portfolio for growth by delivering highly-innovative medicines and transformative care in our chosen business areas, as well as meeting our leverage targets. As we continue to streamline and simplify our portfolio, Takeda is confident that we have found the right partner in Corza Health as the next home for TachoSil®. Corza Health’s expertise in healthcare, commitment to patients, customers and employees, and resources in partnership with GTCR make it well-positioned to ensure continued patient access to TachoSil® and to invest in the product over the long term for their benefit.”
Takeda has sustained the momentum of its divestiture program in 2020. Most recently, Takeda announced the sale of non-core assets in Europe and Canada to Cheplapharm for approximately $562 million USD. In August, Takeda announced an agreement to divest Takeda Consumer Healthcare Company Limited to Blackstone for approximately $2.3 billion USD. In June, Takeda agreed to divest a portfolio of non-core assets sold exclusively in the Asia Pacific region to Celltrion for up to $278 million USD; in April, Takeda announced the sale of non-core products in Europe to Orifarm Group for up to approximately $670 million USD, including the sale of two manufacturing sites in Denmark and Poland; and in March, Takeda announced the sale of non-core products in Latin America to Hypera Pharma for $825 million USD, as well as completed the previously announced sales of non-core assets spanning the Russia-CIS region to STADA and in countries spanning the Near East, Middle East and Africa region to Acino.
Takeda intends to use the proceeds from this transaction to reduce its debt and accelerate de-leveraging toward its target of 2x net debt/adjusted EBITDA within Fiscal Year 2021 –2023. Takeda is committed to rapid deleveraging driven by strong cash flow and divestiture proceeds, while also simplifying our portfolio.
As previously disclosed, Takeda had entered into an agreement for the sale of TachoSil® to Ethicon, a Johnson & Johnson company, in May 2019. Takeda and Ethicon agreed to mutually terminate the transaction in April 2020 as a result of anti-trust concerns raised by the European Commission.
Under the terms of the agreement, upon close, Corza Health will acquire the assets and licenses that support the development and commercialization of TachoSil®, while Takeda will maintain ownership of the manufacturing facility in Linz, Austria. Takeda has entered into a long-term manufacturing services agreement, under which it will continue to manufacture TachoSil® products and supply them to Corza Health.
The agreement is expected to close by March 31, 2021, subject to the satisfaction of customary closing conditions, receipt of required regulatory clearances and, where applicable, satisfaction of local information and/or consultation requirements. Upon close, approximately 60 Takeda employees will have the opportunity to transition to Corza Health.
Nomura is acting as financial advisor to Takeda and Linklaters LLP is acting as Takeda’s legal advisor in this transaction.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
For more information, visit www.takeda.com.
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company
Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
+81 (0) 3-3278-2306
+81 (0) 3-3278-2095
Media outside Japan:
Justine Grosvenor firstname.lastname@example.org
[ +1] 872 226 6701
07.08.2019 Mynewsdesk: DACHSER baut in Neumünster
Der Logistikdienstleister DACHSER startet heute den Bau einer neuen Niederlassung in Neumünster.An der Isarstraße im Industriegebiet Süd entstehen ein Umschlagterminal für Industriegüter sowie für Lebensmittel. Die Investitionssumme beläuft sich auf rund 17,4 ...
06.08.2019 Mynewsdesk: ENCAVIS zentralisiert Zahlungsverkehr und Bankkontenverwaltung mit cloudbasierter Payment-Plattform von TIS
Als Stromanbieter im Bereich Erneuerbare Energien arbeitet die ENCAVIS AG aus Hamburg in einem der Schlüsselmärkte der Zukunft. Das Unternehmen verfolgt daher eine progressive Wachstumsstrategie, die einhergeht mit einer starken Zunahme der Bankenlandschaft. Bankkonten zu reduzieren ist ...
06.08.2019 Mynewsdesk: Der sichere Cloud-Speicher
Viele Anwender schätzen den Komfort von Cloud-Diensten und nutzen Angebote wie Dropbox, Google Drive oder iCloud. In welchem Land ihre Daten gespeichert, wie diese technisch geschützt und welche Datenschutzbestimmungen angewendet werden, wissen nur wenige.»Nutzer von ...
02.08.2019 Mynewsdesk: Leipzig überholt Dortmund und ist jetzt offiziell die achtgrößte Stadt in Deutschland
Leipzig ist weiterhin die am stärksten wachsende Großstadt in Deutschland. Auf der Liste der größten deutschen Metropolen rutschte Leipzig einen Platz nach vorn und hat nach Essen im Jahr 2017 inzwischen auch Dortmund in der Einwohnerzahl überholt. Damit ist Leipzig nach ...
01.08.2019 Mynewsdesk: Kraftstoffpreise geben im Juli trotz Ferienzeit weiter nach
- Super E10 3 Cent, Diesel 1 Cent pro Liter günstiger als im Juni- Super E10 am günstigsten in Bremen, Düsseldorf und Bielefeld und am teuersten in Leipzig, Dresden und Frankfurt- Diesel am günstigsten in Bremen, Düsseldorf und Leipzig sowie am teuersten in München, ...
31.07.2019 Mynewsdesk: Creative Business Support: PLAYMOBIL pro ab August erhältlich
Im August 2019 startet der Vertrieb von PLAYMOBIL pro / Unternehmen, Coaches, Consultants und Workshop-Teilnehmer freuen sich auf ein innovatives Moderationsset für den gesamten Businessbereich / Kreative Unterstützung für Arbeitsprozesse, Ideenfindung und ...
21.10.2020 GlobeNewswire: ISG Index™: Outsourcing-Markt in der EMEA-Region wächst in Q3 durch IT-Outsourcing (ITO)
ISG Index™: Outsourcing-Markt in der EMEA-Region wächst in Q3 durch IT-Outsourcing (ITO) Anstieg der Managed Services um 10 % ggü. Vorjahr bei 36 % Wachstum im Bereich IT-Outsourcing IaaS mit 16 % Anstieg, da Unternehmen ihre Aktivitäten weiter in die Cloud verlagern Der kombinierte Markt nahm um 9 % im Vergleich zu 2019 zu...
21.10.2020 GlobeNewswire: Monument gibt Joint Venture-Vereinbarung für das Tuckanarra-Projekt in Westaustralien bekannt
Monument gibt Joint Venture-Vereinbarung für das Tuckanarra-Projekt in Westaustralien bekannt VANCOUVER, British Columbia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY und FSE: D7Q1), „Monument“ oder das „Unternehmen“, freut sich bekanntzugeben, dass es eine Joint Venture-Vereinbarung (die...
21.10.2020 GlobeNewswire: Sphera bringt innovative Software für Prozesssicherheit und betriebliches Risikomanagement auf den Markt
Sphera bringt innovative Software für Prozesssicherheit und betriebliches Risikomanagement auf den Markt Dynamic Risk Pathways ist die erste Softwareanwendung, die eine Echtzeit-Erfassung mit leicht verständlicher, vorausschauender Visualisierung der Risikopfade bietet. Sie unterstützt Unternehmen dabei...
21.10.2020 GlobeNewswire: Idorsia successfully completes capital increase with gross proceeds of CHF 535.5 million
Idorsia successfully completes capital increase with gross proceeds of CHF 535.5 million • The increased liquidity will be used to prepare for the launch of daridorexant and further fund Idorsia’s diversified pipeline Allschwil, Switzerland – October 21, 2020 Idorsia Ltd (SIX: IDIA) today announced that a total of 23,800,000...
21.10.2020 GlobeNewswire: doTERRA arbeitet in Kenia mit der Weltbank zusammen, um Kleinbauern besseren Zugang zu Finanzmitteln zu ermöglichen
doTERRA arbeitet in Kenia mit der Weltbank zusammen, um Kleinbauern besseren Zugang zu Finanzmitteln zu ermöglichen Entwicklungsprojekt soll Fischereien und hochwertige Agrarketten unterstützen PLEASANT GROVE, Utah und NAIROBI, Kenia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- doTERRA und seine Lieferkettenpartner haben sich mit der...
21.10.2020 GlobeNewswire: Multi-Milliarden-Dollar-Chancen für Betreiber im Bereich der Personal Cloud von Synchronoss und Arthur D. Little aufgezeigt.
Multi-Milliarden-Dollar-Chancen für Betreiber im Bereich der Personal Cloud von Synchronoss und Arthur D. Little aufgezeigt. Marktdynamik stellt Wendepunkt für Umsatzwachstumspotenzial für Betreiber im Bereich der Personal Cloud dar BRIDGEWATER, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Synchronoss Technologies (NASDAQ: SNCR) und...